Dengue Fever Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight |Kino Pharma, Abivax, Plex Pharma, Codagenix, Atea Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dengue Fever pipeline constitutes 10+ key companies continuously working towards developing 10+ Dengue Fever treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Dengue Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Dengue Fever Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dengue Fever Market.

Some of the key takeaways from the Dengue Fever Pipeline Report:

* Companies across the globe are diligently working toward developing novel Dengue Fever treatment therapies with a considerable amount of success over the years.
* Dengue Fever companies working in the treatment market are Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others, are developing therapies for the Dengue Fever treatment

* Emerging Dengue Fever therapies such as - anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others are expected to have a significant impact on the Dengue Fever market in the coming years.
* In Febuary 2024, The TAK-003 vaccine represents a novel approach to combatting dengue fever in regions heavily impacted by the disease.

Dengue Fever Overview

Dengue fever is a viral infection transmitted primarily by the Aedes mosquito, particularly Aedes aegypti. It is caused by the dengue virus, which belongs to the Flaviviridae family. Dengue fever is prevalent in tropical and subtropical regions, including Southeast Asia, the Pacific Islands, the Caribbean, and parts of Central and South America.

Get a Free Sample PDF Report to know more about Dengue Fever Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight [https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Dengue Fever Drugs Under Different Phases of Clinical Development Include:

* Research programme: anti-RNA virus therapeutics - Kino Pharma
* ABX220: Abivax
* Infectious diseases therapeutics Programme: Plex Pharmaceuticals
* CDX DENV: Codagenix
* AT-752: Atea Pharmaceuticals
* LD vehicle-GNP: Emergex Vaccines
* VIS513: Visterra
* JNJ-64281802: Janssen Research & Development
* TV003: Merck & Co.
* V 503: Takeda

Route of Administration

Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Subcutaneous
* Intravenous
* Intramuscular
* Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

* Small molecules
* Proteins
* Monoclonal antibodies
* Product Type

Dengue Fever Pipeline Therapeutics Assessment

* Dengue Fever Assessment by Product Type
* Dengue Fever By Stage and Product Type
* Dengue Fever Assessment by Route of Administration
* Dengue Fever By Stage and Route of Administration
* Dengue Fever Assessment by Molecule Type
* Dengue Fever by Stage and Molecule Type

DelveInsight's Dengue Fever Report covers around 10+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Dengue Fever product details are provided in the report. Download the Dengue Fever pipeline report to learn more about the emerging Dengue Fever therapies [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Dengue Fever Therapeutics Market include:

Key companies developing therapies for Dengue Fever are - Takeda Pharmaceutical Co Ltd, BioNet-Asia Co Ltd, Emergex Vaccines Holding Ltd, Johnson & Johnson, 60 Degrees Pharmaceuticals LLC, and Abivax SA among others.

Dengue Fever Pipeline Analysis:

The Dengue Fever pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Dengue Fever with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Fever Treatment.
* Dengue Fever key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Dengue Fever Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue Fever market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dengue Fever drugs and therapies [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dengue Fever Pipeline Market Drivers

* Fastest spreading mosquito-borne viral disease, search of novel tools and innovative strategies to interrupt transmission of dengue, integration of vector management approaches is encouraged are some of the important factors that are fueling the Dengue Fever Market.

Dengue Fever Pipeline Market Barriers

* However, challenging research due to multiple stereotypes, disease risks may change and shift with climate change in tropical and subtropical areas and other factors are creating obstacles in the Dengue Fever Market growth.

Scope of Dengue Fever Pipeline Drug Insight

* Coverage: Global
* Key Dengue Fever Companies: Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others
* Key Dengue Fever Therapies: anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others
* Dengue Fever Therapeutic Assessment: Dengue Fever current marketed and Dengue Fever emerging therapies
* Dengue Fever Market Dynamics: Dengue Fever market drivers and Dengue Fever market barriers

Request for Sample PDF Report for Dengue Fever Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Dengue Fever Report Introduction

2

Dengue Fever Executive Summary

3

Dengue Fever Overview

4

Dengue Fever- Analytical Perspective In-depth Commercial Assessment

5

Dengue Fever Pipeline Therapeutics

6

Dengue Fever Late Stage Products (Phase II/III)

7

Dengue Fever Mid Stage Products (Phase II)

8

Dengue Fever Early Stage Products (Phase I)

9

Dengue Fever Preclinical Stage Products

10

Dengue Fever Therapeutics Assessment

11

Dengue Fever Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Dengue Fever Key Companies

14

Dengue Fever Key Products

15

Dengue Fever Unmet Needs

16

Dengue Fever Market Drivers and Barriers

17

Dengue Fever Future Perspectives and Conclusion

18

Dengue Fever Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dengue-fever-pipeline-and-clinical-trials-assessment-2024-updates-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-kino-pharma-abivax-plex-pharma-codagenix-atea-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.